- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07838883
Rare Disease Registry Database for Movement Disorders in Southern Anhui Province (W-MoSCA)
According to the World Health Organization (WHO) definition, a rare disease is a disease affecting fewer than 6.5 people per 10,000; in China, it generally refers to diseases with a prevalence of less than 1/10,000 (i.e., with a total of no more than 140,000 patients). Such diseases are mostly hereditary or congenital in origin. Patients with rare diseases often present with complex symptoms, most of which are neurological. Although a large number of rare diseases have been identified, the small number of patients with each disease and the diversity of symptoms make early diagnosis difficult and render large-sample clinical trials challenging. Consequently, most rare diseases lack curative treatments; available therapies are of limited efficacy or prohibitive cost, ultimately leading to severe disability or death and imposing a substantial socioeconomic burden. This study establishes a registry for motor neuron diseases (MND), spinocerebellar ataxias (SCAs), hereditary muscular dystrophy (HMD), and hereditary spastic paraplegia (HSP). Owing to the low incidence, complex clinical diagnosis, unclear pathogenic mechanisms, and strong genetic heterogeneity, epidemiological data on rare motor neuron diseases are limited, further increasing the difficulty of biomarker screening and targeted therapeutic development. Therefore, there is an urgent need to establish a comprehensive registry and to obtain reliable evidence on risk factors and early diagnosis through research. This study aims to establish a registry of rare neurological diseases in the southern Anhui Province and to build a high-quality biobank of human biological resources.
Aperçu de l'étude
Statut
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Xianjin Shang, Prof.
- Numéro de téléphone: 86 151 5530 0503
- E-mail: shangxj2013@wnmc.edu.cn
Lieux d'étude
-
-
Anhui
-
Wuhu, Anhui, Chine, 241001
- Recrutement
- First affiliated hospital of Wannan Medical University
-
Contact:
- Xianjin Shang, Prof.
- Numéro de téléphone: 86 15155300503
- E-mail: shangxj2013@wnmc.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
These rare movement-related neurological diseases are all characterized primarily by gait abnormalities; although muscle weakness, ataxia, poor muscle endurance, and spastic paraplegia are their typical presentations, respectively, they share overlapping motor neurological symptoms and similar early clinical manifestations.
La description
Inclusion Criteria:
- Adults aged 19 years or older who are capable of giving informed consent.
- Definitive diagnosis of one of the following diseases: (1) amyotrophic lateral sclerosis (diagnosed according to the revised El Escorial criteria, Awaji criteria, or Gold Coast criteria); (2) spinocerebellar ataxia; (3) muscular dystrophy; (4) hereditary spastic paraplegia.
- Others: primary lateral sclerosis, progressive muscular atrophy, ALS-FTD syndrome, progressive bulbar palsy, benign focal muscular atrophy, and other motor neuron diseases.
Exclusion Criteria:
- Patients with concomitant systemic diseases;
- Vulnerable research subjects: minors and patients with cognitive impairment;
- Participants from whom clinical information and human biological samples cannot be collected;
- Other patients judged by the investigators to be unsuitable for participation in the study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
|---|
|
Motor Neuron Diseases
Patient diagnosis, clinical assessment, treatment, and biological sample collection |
|
spinocerebellar ataxia(SCAs)
Patient diagnosis, clinical assessment, treatment, and biological sample collection |
|
hereditary muscular dystrophy
Patient diagnosis, clinical assessment, treatment, and biological sample collection |
|
hereditary spastic paraplegia
Patient diagnosis, clinical assessment, treatment, and biological sample collection |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Amyotrophic Lateral Sclerosis Functional Rating Scale (K-ALSFRS-R)
Délai: through study completion, an average of 3 months
|
Total score: 0 to 48 points 48 points: completely normal function 0 points: complete loss of function in the corresponding dimension. The lower the score, the more severe the functional disability. |
through study completion, an average of 3 months
|
|
Hereditary spastic paraplegia (HSP): Spastic Paraplegia Rating Scale (SPRS)
Délai: through study completion, an average of one year
|
Including 13 items, each item is scored from 0 to 4 (0 = normal, 4 = most serious impairment) Total score: 0 to 52 points; the higher the score, the more serious the condition |
through study completion, an average of one year
|
|
Scale for the Assessment and Rating of Ataxia (SARA)
Délai: through study completion, an average of one year
|
Including 8 items, each item has a different maximum score. Total score: 0 to 40 points; the higher the score, the more severe the ataxia. 0 points: no ataxia. 40 points: the most severe ataxia. |
through study completion, an average of one year
|
|
6-minute walk test for hereditary muscular dystrophy
Délai: through study completion, an average of 1 year
|
The subjects walked continuously for 6 minutes as fast and safely as possible in a flat hard corridor; they can use the patient's daily walkers, crutches, and orthopedic braces; they are allowed to stop and rest in the middle (timer does not stop), and the total walking meters PMC is recorded at the end of 6 minutes. |
through study completion, an average of 1 year
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Cao Y, Zheng H, Zhu Z, Yao L, Tian W, Cao L. Clinical and Genetic Spectrum in a Large Cohort of Hereditary Spastic Paraplegia. Mov Disord. 2024 Apr;39(4):651-662. doi: 10.1002/mds.29728. Epub 2024 Jan 31.
- Tong YR, Geng C, Guan YZ, Zhao YH, Ren HT, Yao FX, Ling C, Wang DC, Chen L, Cui LY, Zhang SY, Dai Y. A Comprehensive Analysis of 2013 Dystrophinopathies in China: A Report From National Rare Disease Center. Front Neurol. 2020 Sep 30;11:572006. doi: 10.3389/fneur.2020.572006. eCollection 2020.
- Xu L, Chen L, Wang S, Feng J, Liu L, Liu G, Wang J, Zhan S, Gao P, Fan D. Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry. 2020 May;91(5):520-525. doi: 10.1136/jnnp-2019-322317. Epub 2020 Mar 5.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Maladies du cerveau
- Maladies du système nerveux central
- Maladies du système nerveux
- Maladies neuromusculaires
- Maladies génétiques, innées
- Maladies du système nerveux périphérique
- Maladies neurodégénératives
- Anomalies congénitales
- Troubles hérédodégénératifs, système nerveux
- Maladies de la moelle épinière
- Malformations du système nerveux
- Dyskinésies
- Polyneuropathies
- Maladies cérébelleuses
- Ataxie cérébelleuse
- Dégénérescences spinocérébelleuses
- Neuropathie sensorielle et motrice héréditaire
- Ataxie
- Maladies et anomalies congénitales, héréditaires et néonatales
- Maladie du motoneurone
- Ataxies spinocérébelleuses
- Paraplégie spastique, héréditaire
Autres numéros d'identification d'étude
- W-MoSCA2026200
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .